ZOETIS INC Reports Second Quarter Earnings Results for FY2023

August 10, 2023

🌥️Earnings Overview

On August 8 2023, ZOETIS INC ($NYSE:ZTS) reported total revenue of USD 2180.0 million and net income of USD 671.0 million for their second quarter FY2023, which ended on June 30 2023. This represented a 6.2% increase in revenue and a 26.8% increase in net income compared to the same period in the previous year.

Market Price

On Tuesday, ZOETIS INC reported its second-quarter earnings results for FY2023, showing a strong increase in stock prices. At the opening bell, the stock was at $182.2 and closed at $189.3, up by 4.8% from the previous day’s closing price of 180.7. This marked the highest close for the company in over a year. The company reported strong results across all its divisions, including animal health, animal nutrition and aquaculture, demonstrating its commitment to providing innovative solutions to the healthcare industry.

In addition, the company performed well in areas such as medical devices, vaccine and pharmaceuticals, and food safety. Zoetis also saw a strong uptick in demand from pet owners, driven by increasing pet ownership and an aging pet population. This contributed to an increase in sales of animal medicines and vaccines. Overall, the strong second quarter earnings results were in line with what analysts had expected. With this strong performance, Zoetis is well-positioned to continue its impressive growth trajectory and deliver long-term shareholder value. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Zoetis Inc. More…

    Total Revenues Net Income Net Margin
    8.22k 2.21k 27.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Zoetis Inc. More…

    Operations Investing Financing
    2k -858 -2.04k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    13.75k 9.13k 10.04
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Zoetis Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    9.1% 11.3% 37.3%
    FCF Margin ROE ROA
    15.6% 42.0% 13.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has completed an analysis of ZOETIS INC‘s fundamentals. Our Risk Rating identifies ZOETIS INC as a medium risk investment in terms of financial and business aspects. In our review of the balance sheet, we detected one risk warning that requires further investigation. Interested investors should register with us to gain access to more information about the warning. By assessing the financial and business risks associated with any investment, GoodWhale ensures our clients make informed decisions. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.

    – BioGaia AB ($OTCPK:BIOGY)

    Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

    Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

    – Krka d.d. ($LTS:0HLK)

    Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.

    – Phibro Animal Health Corp ($NASDAQ:PAHC)

    Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.


    Investors in ZOETIS INC saw positive returns on August 8, 2023, following the company’s second quarter earnings release. Total revenue was up 6.2% year-on-year, coming in at USD 2180.0 million, while net income was up 26.8% to USD 671.0 million. This strong performance highlights the company’s strong financial position and is likely to be seen as a positive sign for investors. Going forward, investors should be monitoring the company’s progress and performance to ensure that these strong results can be maintained.

    Recent Posts

    Leave a Comment